FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022671624> ?p ?o ?g. }

• W2022671624 endingPage "C116" @default.
• W2022671624 startingPage "C116" @default.
• W2022671624 abstract "Abstract Lenvatinib is an orally administered, tyrosine kinase inhibitor targeting VEGFR1–3, FGFR1–4, PDGFRβ, RET, and KIT, which is currently being studied in patients with solid tumors in doses of 24 mg daily. A previous study in patients with solid tumors treated continuously with 25 mg QD, suggested that Lenvatinib had little or no effect on the QTc interval (mean change-from-baseline QTcF [ΔQTcF] of 2.4 ms). This thorough QT study was conducted to exclude a QTc effect of concern in preparation for phase 3 development. Methods: The effect of Lenvatinib on the QTc interval and on other ECG parameters was studied in 52 healthy male and female volunteers in a randomized, partially double-blinded, 3-way crossover study. The effect of a single dose of 32 mg Lenvatinib on ECG parameters was assessed and the study's ability to detect a small QTc effect was tested by the inclusion of a positive control, moxifloxacin. Using 12-lead continuous ECG recordings, up to 10 ECGs were collected at each predefined time point before and after dosing. Measurements were performed with the High Precision QT (HAQT) measurement technique. Results: The mean placebo-corrected change from baseline QTcF (ΔΔQTcF) was negative at most timepoints post-dosing and the upper bound of the 90% confidence interval did not exceed 10 ms at any timepoint. Concentration effect modeling (CEM) demonstrated a negative slope of −0.0045 ms/ng/mL with an intercept of −2.96 ms. At the observed geometric mean peak Lenvatinib plasma concentration (370 ng/mL; 90% CI 332 to 412), the predicted ΔΔQTcF was −4.62 ms (90% CI: −5.86 to −3.38), which is consistent with the time matched analysis. Based on CEM, it can also be shown that the ΔΔQTcF effect at plasma concentration up to levels observed in patients with impaired clearance of the drug will not exceed 10 ms. Moxifloxacin prolonged ΔΔQTcF with a peak effect of 12.6 ms and the lower bound of the 90% confidence interval (CI) exceeded 5 ms at all 4 pre-specified timepoints, thereby demonstrating the study's ability to detect a small QT effect. The precision of the QTc measurement using High Precision QT was very high with a standard deviation of ΔQTcF across treatments of 5.85 ms. No effect of Lenvatinib on the PR and QRS intervals or on T-wave morphology was observed. Lenvatinib seemed to exert a mild heart rate lowering effect of 3 to 8 beats per minute, without correlation to the peak plasma levels. The incidence of treatment emergent AEs (TEAEs) in subjects who received Lenvatinib was similar to that observed in subjects who received moxifloxacin or placebo. Most TEAEs were mild in severity. No severe AEs were observed in this study. Conclusion: In this Phase I thorough QTc study in healthy subjects, at clinically relevant plasma concentrations, Lenvatinib did not prolong the QTc interval and had no other clinically relevant ECG effects. A single dose of 32 mg Lenvatinib was safe and well tolerated. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C116." @default.
• W2022671624 created "2016-06-24" @default.
• W2022671624 creator A5030588946 @default.
• W2022671624 creator A5033929431 @default.
• W2022671624 creator A5038808458 @default.
• W2022671624 creator A5040398689 @default.
• W2022671624 creator A5056514511 @default.
• W2022671624 creator A5084029170 @default.
• W2022671624 date "2011-11-01" @default.
• W2022671624 modified "2023-09-22" @default.
• W2022671624 title "Abstract C116: Lenvatinib (E7080) does not prolong the QTc interval: Results from a thorough QT study in healthy volunteers." @default.
• W2022671624 doi "https://doi.org/10.1158/1535-7163.targ-11-c116" @default.
• W2022671624 hasPublicationYear "2011" @default.
• W2022671624 type Work @default.
• W2022671624 sameAs 2022671624 @default.
• W2022671624 citedByCount "3" @default.
• W2022671624 countsByYear W20226716242012 @default.
• W2022671624 countsByYear W20226716242015 @default.
• W2022671624 crossrefType "journal-article" @default.
• W2022671624 hasAuthorship W2022671624A5030588946 @default.
• W2022671624 hasAuthorship W2022671624A5033929431 @default.
• W2022671624 hasAuthorship W2022671624A5038808458 @default.
• W2022671624 hasAuthorship W2022671624A5040398689 @default.
• W2022671624 hasAuthorship W2022671624A5056514511 @default.
• W2022671624 hasAuthorship W2022671624A5084029170 @default.
• W2022671624 hasConcept C118441451 @default.
• W2022671624 hasConcept C121608353 @default.
• W2022671624 hasConcept C126322002 @default.
• W2022671624 hasConcept C142724271 @default.
• W2022671624 hasConcept C164705383 @default.
• W2022671624 hasConcept C204787440 @default.
• W2022671624 hasConcept C27081682 @default.
• W2022671624 hasConcept C2776264508 @default.
• W2022671624 hasConcept C2777288759 @default.
• W2022671624 hasConcept C2778836808 @default.
• W2022671624 hasConcept C2779761222 @default.
• W2022671624 hasConcept C501593827 @default.
• W2022671624 hasConcept C71924100 @default.
• W2022671624 hasConcept C86803240 @default.
• W2022671624 hasConcept C87813604 @default.
• W2022671624 hasConcept C89423630 @default.
• W2022671624 hasConcept C98274493 @default.
• W2022671624 hasConceptScore W2022671624C118441451 @default.
• W2022671624 hasConceptScore W2022671624C121608353 @default.
• W2022671624 hasConceptScore W2022671624C126322002 @default.
• W2022671624 hasConceptScore W2022671624C142724271 @default.
• W2022671624 hasConceptScore W2022671624C164705383 @default.
• W2022671624 hasConceptScore W2022671624C204787440 @default.
• W2022671624 hasConceptScore W2022671624C27081682 @default.
• W2022671624 hasConceptScore W2022671624C2776264508 @default.
• W2022671624 hasConceptScore W2022671624C2777288759 @default.
• W2022671624 hasConceptScore W2022671624C2778836808 @default.
• W2022671624 hasConceptScore W2022671624C2779761222 @default.
• W2022671624 hasConceptScore W2022671624C501593827 @default.
• W2022671624 hasConceptScore W2022671624C71924100 @default.
• W2022671624 hasConceptScore W2022671624C86803240 @default.
• W2022671624 hasConceptScore W2022671624C87813604 @default.
• W2022671624 hasConceptScore W2022671624C89423630 @default.
• W2022671624 hasConceptScore W2022671624C98274493 @default.
• W2022671624 hasIssue "11_Supplement" @default.
• W2022671624 hasLocation W20226716241 @default.
• W2022671624 hasOpenAccess W2022671624 @default.
• W2022671624 hasPrimaryLocation W20226716241 @default.
• W2022671624 hasRelatedWork W1604467628 @default.
• W2022671624 hasRelatedWork W2038316072 @default.
• W2022671624 hasRelatedWork W2059530273 @default.
• W2022671624 hasRelatedWork W2087694690 @default.
• W2022671624 hasRelatedWork W2089254981 @default.
• W2022671624 hasRelatedWork W2094255619 @default.
• W2022671624 hasRelatedWork W2130165766 @default.
• W2022671624 hasRelatedWork W2143920140 @default.
• W2022671624 hasRelatedWork W2332733266 @default.
• W2022671624 hasRelatedWork W3157362757 @default.
• W2022671624 hasVolume "10" @default.
• W2022671624 isParatext "false" @default.
• W2022671624 isRetracted "false" @default.
• W2022671624 magId "2022671624" @default.
• W2022671624 workType "article" @default.